WO2007058992A3 - Mutations and polymorphisms of hdac6 - Google Patents

Mutations and polymorphisms of hdac6 Download PDF

Info

Publication number
WO2007058992A3
WO2007058992A3 PCT/US2006/043899 US2006043899W WO2007058992A3 WO 2007058992 A3 WO2007058992 A3 WO 2007058992A3 US 2006043899 W US2006043899 W US 2006043899W WO 2007058992 A3 WO2007058992 A3 WO 2007058992A3
Authority
WO
WIPO (PCT)
Prior art keywords
hdac6
mutations
mutant
polymorphisms
polymorphic
Prior art date
Application number
PCT/US2006/043899
Other languages
French (fr)
Other versions
WO2007058992A2 (en
Inventor
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Kenneth Wayne Culver, Jian Zhu, Stan Lilleberg filed Critical Novartis Ag
Publication of WO2007058992A2 publication Critical patent/WO2007058992A2/en
Publication of WO2007058992A3 publication Critical patent/WO2007058992A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC6 gene. The invention provides new HDAC6 mutations and SNPs5 useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC6 mutations of the invention, expression vectors encoding the HDAC6 mutant polypeptides of the invention and organisms that express the HDAC6 mutant and polymorphic ' polynucleotides and/or HDAC6 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC6 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
PCT/US2006/043899 2005-11-14 2006-11-13 Mutations and polymorphisms of hdac6 WO2007058992A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73645505P 2005-11-14 2005-11-14
US60/736,455 2005-11-14

Publications (2)

Publication Number Publication Date
WO2007058992A2 WO2007058992A2 (en) 2007-05-24
WO2007058992A3 true WO2007058992A3 (en) 2007-07-12

Family

ID=37947953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043899 WO2007058992A2 (en) 2005-11-14 2006-11-13 Mutations and polymorphisms of hdac6

Country Status (1)

Country Link
WO (1) WO2007058992A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2344889A2 (en) * 2008-10-14 2011-07-20 Oregon Health and Science University Methods for the selection of therapeutic treatments for cancer
WO2011006908A2 (en) * 2009-07-16 2011-01-20 Royal College Of Surgeons In Ireland Metal complexes having dual histone deacetylase inhibitory and dna-binding activity
WO2013041407A1 (en) * 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (en) * 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (en) * 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ACHARYA MILIN R ET AL: "Rational development of histone deacetylase inhibitors as anticancer agents: a review.", MOLECULAR PHARMACOLOGY OCT 2005, vol. 68, no. 4, October 2005 (2005-10-01), pages 917 - 932, XP002423309, ISSN: 0026-895X *
BRADBURY C A ET AL: "Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K OCT 2005, vol. 19, no. 10, October 2005 (2005-10-01), pages 1751 - 1759, XP002431357, ISSN: 0887-6924 *
LILLEBERG S L ET AL: "High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, vol. 1022, June 2004 (2004-06-01), pages 250 - 256, XP002392437, ISSN: 0077-8923 *
MAI ANTONELLO ET AL: "HISTONE DEACETYLATION IN EPIGENETICS: AN ATTRACTIVE TARGET FOR ANTICANCER THERAPY", MEDICINAL RESEARCH REVIEWS, NEW YORK, NY, US, vol. 25, no. 3, May 2005 (2005-05-01), pages 261 - 309, XP009075075, ISSN: 0198-6325 *
PARK J M ET AL: "no association between polymorphisms in the histone deacetylase genes and the risk of lung cancer", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, AMERICAN ASSOCIATION FOR CANCER RESEARCH,, US, vol. 14, no. 7, July 2005 (2005-07-01), pages 1841 - 1843, XP002424811, ISSN: 1055-9965 *
ZHANG ZHENHUAN ET AL: "HDAC6 expression is correlated with better survival in breast cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 OCT 2004, vol. 10, no. 20, 15 October 2004 (2004-10-15), pages 6962 - 6968, XP002431356, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
WO2007058992A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
WO2006130527A3 (en) Mutations and polymorphisms of fibroblast growth factor receptor 1
WO2005033652A3 (en) Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2006135879A3 (en) Diagnosis and prognosis of diabetes
WO2004044557A3 (en) Non-invasive measurement of analytes
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
WO2006128042A3 (en) Methods of identifying mutations in nucleic acid
WO2002086448A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
EP1813947A4 (en) Method of examining alzheimer's disease and diagnostic reagent
WO2005114190A3 (en) Methods of identifying biomarkers
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
WO2006073682A3 (en) Diagnostic test
EP2293074A3 (en) Method for diagnosing neuro-degenerative disease
WO2001040517A3 (en) Evaluating and predicting clinical outcomes by gene expression analysis
WO2008060777A3 (en) Elisa for vegf
WO2006110478A3 (en) Mutations and polymorphisms of epidermal growth factor receptor
EP2287340A3 (en) Method for diagnosis and treatment of a mental disease
WO2002022879A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2007022041A3 (en) Mutations and polymorphisms of hdac3
BR0111473A (en) Methods for screening an individual for glycogen storage disease, for screening an individual for pomp disease, for monitoring the clinical condition of an individual with pomp disease, to estimate the efficacy of a therapeutic regimen for an individual with disease pompe and to determine the concentration of an oligosaccharide in a biological sample
ATE432997T1 (en) THERAPY MONITORING FOR TUMORS USING ACC133 MRNA
WO2005118403A3 (en) Methods for detecting gene expression in peripheral blood cells and uses thereof
WO2007030455A3 (en) Mutations and polymorphisms of hdac10
WO2007058992A3 (en) Mutations and polymorphisms of hdac6

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06837391

Country of ref document: EP

Kind code of ref document: A2